Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma

Molecular Cell

Volumn 57, Issue 5, 2015, Pages 784-796

  Litvin, Oren ^a   Schwartz, Sarit ^b   Wan, Zhenmao ^a   Schild, Tanya ^a   Rocco, Mark ^a   Oh, NulLoren ^a   Chen, Bo Juen ^a   Goddard, Noel ^a   Pratilas, Christine ^b   Pe'er, Dana ^a  

^a Columbia University ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RANTES; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DIPHENYLAMINE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITF PROTEIN, HUMAN; STAT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CELL SURVIVAL; CLUSTER ANALYSIS; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; DIPHENYLAMINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MODELS, GENETIC; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STAT1 TRANSCRIPTION FACTOR;

EID: 84923880997     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2014.12.030     Document Type: Article

References (35)

1. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
2. Bratton S.B., Salvesen G.S. Regulation of the Apaf-1-caspase-9 apoptosome. J.Cell Sci. 2010, 123:3209-3214.
3. Dai B., Meng J., Peyton M., Girard L., Bornmann W.G., Ji L., Minna J.D., Fang B., Roth J.A. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011, 71:3658-3668.
4. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
5. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819.
6. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
7. Hecker M., Hartmann C., Kandulski O., Paap B.K., Koczan D., Thiesen H.J., Zettl U.K. Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood. Mol. Neurobiol. 2013, 48:737-756.
8. Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., Nickerson E., Auclair D., Li L., Place C., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
9. Jackson D.P., Watling D., Rogers N.C., Banks R.E., Kerr I.M., Selby P.J., Patel P.M. The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res. 2003, 13:219-229.
10. Johannessen C.M., Johnson L.A., Piccioni F., Townes A., Frederick D.T., Donahue M.K., Narayan R., Flaherty K.T., Wargo J.A., Root D.E., Garraway L.A. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013, 504:138-142.
11. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., Halilovic E., Persaud Y., Xing F., Viale A., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 2010, 107:14903-14908.
12. Leaman D.W., Chawla-Sarkar M., Jacobs B., Vyas K., Sun Y., Ozdemir A., Yi T., Williams B.R., Borden E.C. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. J.Interferon Cytokine Res. 2003, 23:745-756.
13. Levy C., Khaled M., Fisher D.E. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 2006, 12:406-414.
14. Lito P., Pratilas C.A., Joseph E.W., Tadi M., Halilovic E., Zubrowski M., Huang A., Wong W.L., Callahan M.K., Merghoub T., et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22:668-682.
15. Majewski N., Nogueira V., Bhaskar P., Coy P.E., Skeen J.E., Gottlob K., Chandel N.S., Thompson C.B., Robey R.B., Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 2004, 16:819-830.
16. Naylor M.F., Brown S., Quinlan C., Pitha J.V., Evertt M.A. 9p21 deletions in primary melanoma. Dermatol. Online J. 1997, 3:1.
17. Niepel M., Hafner M., Pace E.A., Chung M., Chai D.H., Zhou L., Schoeberl B., Sorger P.K. Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci. Signal. 2013, 6:ra84.
18. Niepel M., Hafner M., Pace E.A., Chung M., Chai D.H., Zhou L., Muhlich J.L., Schoeberl B., Sorger P.K. Analysis of growth factor signaling in genetically diverse breast cancer lines. BMC Biol. 2014, 12:20.
19. Paraiso K.H., Xiang Y., Rebecca V.W., Abel E.V., Chen Y.A., Munko A.C., Wood E., Fedorenko I.V., Sondak V.K., Anderson A.R., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011, 71:2750-2760.
20. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
21. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
22. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
23. Reed J.A., Loganzo F., Shea C.R., Walker G.J., Flores J.F., Glendening J.M., Bogdany J.K., Shiel M.J., Haluska F.G., Fountain J.W., et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995, 55:2713-2718.
24. Riedl S.J., Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 2004, 5:897-907.
25. Sachs K., Perez O., Pe'er D., Lauffenburger D.A., Nolan G.P. Causal protein-signaling networks derived from multiparameter single-cell data. Science 2005, 308:523-529.
26. Sancéau J., Hiscott J., Delattre O., Wietzerbin J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 2000, 19:3372-3383.
27. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N.Engl. J. Med. 2001, 344:783-792.
28. Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., McCombie R., Herman J.G., Gerald W.L., Lazebnik Y.A., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
29. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
30. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N.Engl. J. Med. 2012, 366:707-714.
31. Storey J.D., Tibshirani R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 2003, 100:9440-9445.
32. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
33. Weichselbaum R.R., Ishwaran H., Yoon T., Nuyten D.S., Baker S.W., Khodarev N., Su A.W., Shaikh A.Y., Roach P., Kreike B., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 2008, 105:18490-18495.
34. Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.B., Gallardo H., Liu C., Merghoub T., Hefter B., et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012, 31:446-457.
35. Zhang J., Xiao Z., Lai D., Sun J., He C., Chu Z., Ye H., Chen S., Wang J. miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br. J. Cancer 2012, 107:352-359.